Your browser doesn't support javascript.
loading
Structural characterization of M8C10, a neutralizing antibody targeting a highly conserved prefusion-specific epitope on the metapneumovirus fusion trimerization interface.
Xiao, Xiao; Wen, Zhiyun; Chen, Qing; Shipman, Jennifer M; Kostas, James; Reid, John C; Warren, Christopher; Tang, Aimin; Luo, Bin; O'Donnell, Gregory; Fridman, Arthur; Chen, Zhifeng; Vora, Kalpit A; Zhang, Lan; Su, Hua-Poo; Eddins, Michael J.
Afiliación
  • Xiao X; Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Wen Z; Discovery Biologics, Merck & Co., Inc., Boston, Massachusetts, USA.
  • Chen Q; MRL Postdoctoral Research Program, Merck & Co., Inc., Kenilworth, New Jersey, USA.
  • Shipman JM; Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Kostas J; Protein and Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Reid JC; Protein and Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Warren C; Protein and Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Tang A; Protein and Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Luo B; Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • O'Donnell G; Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Fridman A; Quantitative Biosciences, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Chen Z; Quantitative Biosciences, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Vora KA; Data Science and Scientific Informatics, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Zhang L; Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Su H-P; Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA.
  • Eddins MJ; Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA.
J Virol ; 97(12): e0105223, 2023 Dec 21.
Article en En | MEDLINE | ID: mdl-38032197
ABSTRACT
IMPORTANCE Human metapneumovirus (hMPV) is a common pathogen causing lower respiratory tract infections worldwide and can develop severe symptoms in high-risk populations such as infants, the elderly, and immunocompromised patients. There are no approved hMPV vaccines or neutralizing antibodies available for therapeutic or prophylactic use. The trimeric hMPV fusion F protein is the major target of neutralizing antibodies in human sera. Understanding the immune recognition of antibodies to hMPV-F antigen will provide critical insights into developing efficacious hMPV monoclonal antibodies and vaccines.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Paramyxoviridae / Metapneumovirus Límite: Aged / Humans Idioma: En Revista: J Virol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Paramyxoviridae / Metapneumovirus Límite: Aged / Humans Idioma: En Revista: J Virol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos